Loading…
Syndax Pharmaceuticals, Inc. is projected to rise to $23.55 by 2027, a +21% move from its current price of $19.48. SNDX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $18.99 | $19.48 | $19.98 | -0.01% |
| Aug 2 | $18.79 | $19.48 | $20.19 | -0.02% |
| Aug 3 | $18.64 | $19.47 | $20.35 | -0.04% |
| Aug 4 | $18.51 | $19.47 | $20.48 | -0.05% |
| Aug 5 | $18.40 | $19.47 | $20.60 | -0.06% |
| Aug 6 | $18.30 | $19.47 | $20.71 | -0.07% |
| Aug 7 | $18.20 | $19.46 | $20.81 | -0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.20 | $19.46 | $20.81 | -0.08% |
| Week 2 | $17.69 | $19.45 | $21.38 | -0.16% |
| Week 3 | $17.30 | $19.43 | $21.82 | -0.25% |
| Week 4 | $16.98 | $19.42 | $22.20 | -0.33% |
| Week 5 | $16.70 | $19.40 | $22.53 | -0.41% |
| Week 6 | $16.45 | $19.38 | $22.84 | -0.49% |
| Week 7 | $16.22 | $19.37 | $23.12 | -0.57% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops therapies for the treatment of cancer. Incorporated in 2005 and headquartered in New York, New York, it operates in the healthcare sector.
Its lead product candidates include Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
The company pipeline also includes revumenib for the treatment of R/R acute myeloid leukemia (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor.
Syndax Pharmaceuticals, Inc. (SNDX) is a healthcare stock with a current price of $19.63 and a market capitalization of $1.74B. It is ranked 2067 in market listings, reflecting its position within the broader market. The stock trades within the healthcare sector, reflecting its focus on cancer therapies.
The overall price outlook suggests upside potential beyond 2026, as the year-by-year forecast shows rising averages and positive momentum into the 2030s and beyond. The 2026 average is $19.63, with a path toward higher forecasts such as $32.94 by 2030 and $134.56 by 2050, supported by bullish sentiment in later years. These figures indicate a long-run elevation in expected value, though they are estimates and not guarantees.
Investors should note that the forecast implies growth in price over time, but actual outcomes depend on market conditions and company developments. The figures provided are intended to outline a directional outlook rather than promise results.
A major floor 21.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.5% away) — a key level to hold.
The nearest ceiling, 27.5% above — a clean break opens room to run.
A major ceiling 38.3% above — clearing it would confirm fresh momentum.
Key SNDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SNDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.93 | Sell | $19.98 | Sell |
| MA 10 | $21.06 | Sell | $20.74 | Sell |
| MA 20 | $22.20 | Sell | $21.22 | Sell |
| MA 50 | $20.42 | Sell | $21.10 | Sell |
| MA 100 | $21.60 | Sell | $20.92 | Sell |
| MA 200 | $20.34 | Sell | $19.95 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.02 | Neutral |
| Stoch RSI (14) | 7.12 | Buy |
| CCI (20) | -139.59 | Sell |
| Williams %R (14) | -94.70 | Info |
| MACD (12,26,9) | -0.53 | Sell |
| ROC (12) | -19.27 | Sell |
| Bollinger %B (20,2) | 0.07 | Neutral |
| Stochastic %K (14) | 5.30 | Buy |
| TRIX (15) | 0.24 | Buy |
| Awesome (5,34) | -1.24 | Sell |
| Ultimate (7,14,28) | 18.30 | Buy |
| Momentum (10) | -3.23 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 18.95 | Buy |
| ADX (14) | 21.22 | Sell |
| ATR (14) | 0.56 | Info |
The 30-day technical picture is NEUTRAL. RSI14 sits at 40, suggesting slightly cooled momentum relative to overbought/oversold extremes. The short-term moving averages show SMA50 at $20.46 and SMA200 at $20.29, placing the price near a confluence of near-term resistance and longer-term support.
Key levels to watch are support at $18.25 and resistance at $24.84. The 30-day price range runs from a low of $16.58 to a high of $23.24, indicating a relatively wide trading band in the near term. Annualized volatility stands at 50, underscoring meaningful variability in price movements over a year.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.96 | $19.48 | $25.07 | 0% | Neutral | |
| $18.90 | $23.55 | $30.93 | +21% | Bullish | |
| $21.12 | $27.00 | $36.74 | +39% | Bullish | |
| $23.02 | $30.07 | $42.06 | +54% | Bullish | |
| $23.39 | $31.13 | $44.55 | +60% | Bullish | |
| $23.70 | $32.08 | $46.85 | +65% | Bullish | |
| $24.36 | $33.52 | $49.83 | +72% | Bullish | |
| $25.41 | $35.48 | $53.63 | +82% | Bullish | |
| $31.42 | $44.50 | $68.27 | +128% | Bullish | |
| $34.10 | $48.94 | $76.14 | +151% | Bullish | |
| $41.97 | $64.02 | $105.62 | +229% | Bullish | |
| $70.36 | $119.03 | $213.97 | +511% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $16.96 | $19.48 | $22.72 | +0.00% |
| August 2026 | $16.73 | $19.60 | $23.48 | +0.62% |
| September 2026 | $16.32 | $19.27 | $23.38 | -1.67% |
| October 2026 | $16.57 | $19.69 | $24.13 | +2.18% |
| November 2026 | $17.05 | $20.37 | $25.15 | +3.41% |
| December 2026 | $16.80 | $20.16 | $25.07 | -1.01% |
Click any year to see its month-by-month SNDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SNDX price prediction for 2026 points to an average of $19.48 (low $16.96, high $25.07) — a potential gain of 0% on today's $19.48. Price action looks broadly range-bound.
In 2027, SNDX is projected to trade between $18.90 and $30.93, averaging $23.55 — a potential gain of +21% from today's $19.48. That is up +21% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Syndax Pharmaceuticals, Inc.'s 2028 outlook centres on $27.00, within a $21.12 to $36.74 range. That is up +15% on the projected 2027 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2029, SNDX could reach as high as $42.06, with a base case around $30.07 and support toward $23.02 — roughly +54% from $19.48. Buyers look set to stay in control over this stretch.
Expect SNDX to range from $23.39 to $44.55 through 2030. The $31.13 average target implies a +60% move from current prices. That is up +4% on the projected 2029 average. Momentum favours further upside here.
The SNDX price prediction for 2031 points to an average of $32.08 (low $23.70, high $46.85) — a potential gain of +65% on today's $19.48. Buyers look set to stay in control over this stretch.
In 2032, SNDX is projected to trade between $24.36 and $49.83, averaging $33.52 — a potential gain of +72% from today's $19.48. That is up +4% on the projected 2031 average. Momentum favours further upside here.
Syndax Pharmaceuticals, Inc.'s 2033 outlook centres on $35.48, within a $25.41 to $53.63 range. That is up +6% on the projected 2032 average. That marks a +82% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, SNDX could reach as high as $68.27, with a base case around $44.50 and support toward $31.42 — roughly +128% from $19.48. Momentum favours further upside here.
Expect SNDX to range from $34.10 to $76.14 through 2035. The $48.94 average target implies a +151% move from current prices. That is up +10% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The SNDX price prediction for 2040 points to an average of $64.02 (low $41.97, high $105.62) — a potential gain of +229% on today's $19.48. Momentum favours further upside here.
In 2050, SNDX is projected to trade between $70.36 and $213.97, averaging $119.03 — a potential gain of +511% from today's $19.48. That is up +86% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in SNDX today (≈ 51.334702 SNDX) could be worth
$6,110.59
+$5,110.59 (+511%) by 2050 · US Dollar
Based on the average projected SNDX price of $119.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SNDXwould be worth at today's price.
$1,000 invested in SNDX on Jul 30, 2025 (≈ 100.100102 SNDX) would be worth
$1,949.95
+$949.95 (+95.0%) today · 1.95× · US Dollar
Based on a SNDX entry price of $9.99 vs. today's $19.48.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $21.21 | $918.43 | -8.2% |
| 1 month ago | $21.86 | $891.13 | -10.9% |
| 3 months ago | $19.11 | $1,019.36 | +1.9% |
| 6 months ago | $20.31 | $959.13 | -4.1% |
| 1 year ago | $9.99 | $1,949.95 | +95.0% |
| All time (5.0y) ago | $14.98 | $1,300.4 | +30.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SNDX forecast.
Our base-case forecast reaches $39.00 around 2034.
Implied market cap at $39.00: $3.46B
The multi-year forecast paints a bullish trajectory with gains aligning with rising averages and bullish sentiment from 2027 onward. For 2026, the avg price is $19.63 with a neutral sentiment. By 2027 the avg rises to $24.42 with a bullish outlook and a 24.4% ROI.
The path continues higher through 2028 ($28.16, 43.5%), 2029 ($31.49, 60.4%), and 2030 ($32.94, 67.8%).
By 2032 the forecast shows an avg of $35.92 with a max of $53.55 and a bullish sentiment, and by 2033 an avg of $38.72 with a max of $58.69, continuing the bullish trend. The 2040 forecast highlights a substantial rise to an avg of $72.09 with a max of $119.36 and a 267.2% ROI, while the 2050 forecast envisions an avg of $134.56, a max of $242.89, and a 585.5% ROI with bullish sentiment.
These are estimates, not guarantees, and actual results will vary with market conditions, regulatory developments, and company performance. While the outlook shows meaningful upside potential, investors should consider the inherent uncertainties and use these figures as directional guidance rather than a promise of future results.
Tap a question to reveal the answer.
Avg $32.94, min $24.70, max $47.26; ROI 67.8; sentiment BULLISH.
The forecast shows a bullish sentiment from 2027 onward with rising averages and positive ROIs (e.g., 2027 avg $24.42; 2028 $28.16; 2030 $32.94; 2040 $72.09; 2050 $134.56) though these are estimates and not guarantees.
Yes. The 2032 max is $53.55 and the 2033 max is $58.69, indicating that passing $50 is possible within the 2032–2033 window.
Current price is $19.63 and market cap is $1.74B.
Avg $134.56, min $79.09, max $242.89; ROI 585.5; sentiment BULLISH.
Syndax Pharmaceuticals, Inc. Community Discussion
0Share your Syndax Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.